Canntab announces new chief scientific officer
May 20, 2020 By Grow Opportunity staff
Canntab Therapeutics Ltd. is looking to its new chief scientific officer to strengthen its research and development.
Joshi Laxminarayan was announced in his new position on May 15. In his new role as CSO, he brings more than 25 years of his expertise as a pharmaceutical scientist to direct the Canadian biopharmaceutical company’s strategic research and partnership program.
Laxminarayan began his career in India, as a bench chemist. He joined Canntab as a consultant role to the company, then as Director of Quality Assurance & Quality Control, where he assisted with the research and development needed to formulate the company’s current product line.
He specializes in nano emulsion, extended release, and poorly soluble drug development and has played a crucial role in the company’s research and development of cannabis oil inputs.
“Joshi has played an integral part in helping Canntab strengthen its competitive position and relevance, and distinguish itself in the pharmaceutical industry,” says Jeff Renwick, co-founder and CEO of Canntab. “As Canntab enters the next phase of its growth, Mr. Laxminarayan will be invaluable to our continued success, driving us closer to our goal of being the world leader in solid oral dose therapeutic cannabis solutions.”
Canntab Therapeutics is based in Markham, Ont. where it develops a suite of hard pill cannabinoid and terpene-blend formulations in multiple doses and timed-release combinations.
Print this page